Unkategorisiert

AXADIA-AFNET8 and EAST-AFNET4 @ AHA Congress 2022

by

The results of the AXADIA-AFNET8 trial and another EAST-AFNET4 subanalysis will be presented at this year’s AHA congress (Chicago, US) :

Featured Science Session (FS.03): Featured Science in Heart Rhythm Medicine
Apixaban or vitamin K antagonists for stroke prevention in patients with atrial fibrillation on hemodialysis: Results of the randomized AXADIA-AFNET 8 trial
Monday, 7th of November 2022 | 0:20 – 0:30 (CET) / Sunday, 6th of November 2022 | 5:20pm – 5:30pm (CST)
Speaker: Dr. Paulus Kirchhof
More information

Early rhythm control for atrial fibrillation reduces cardiovascular outcomes in patients with prior stroke

by

Patients with atrial fibrillation (AF) and a history of stroke are at high risk of recurrent stroke and cardiovascular complications. A subgroup analysis of the EAST – AFNET 4 trial showed: Early rhythm control therapy is safe and particularly effective in this vulnerable patient group. The results were presented at the World Stroke Congress in Singapore on 26.10.2022 [1], [2].

The EAST – AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention) trial investigated whether rhythm control therapy – using antiarrhythmic drugs or atrial fibrillation ablation – delivered within one year after AF diagnosis improves outcomes. The main study result, published in 2020 [3], demonstrated that early rhythm control therapy reduced cardiovascular events by 21% in patients with AF and comorbidities: Early rhythm control (ERC) with antiarrhythmic drugs and/or AF ablation reduced the primary outcome, a composite of cardiovascular death, stroke, and hospitalization for worsening heart failure or acute coronary syndrome, in 2789 patients with early AF and cardiovascular risk factors compared to usual care (UC) over a 5-year follow-up time.

EAST-AFNET 4 @ World Stroke Congress– WSC 2022

by

Session 0880 – Plenary 01: Opening, Presentation of Award and Late Breaking Trials (ID 294) Early rhythm-control therapy for atrial fibrillation in patients with history of stroke in the EAST-AFNET4 trial
Wednesday, 26th of October 2022 | / 12:10 – 12:20 pm (CEST)/ 18:10 – 18:20 pm (SGT), room “Hall 406”
Speaker: Märit Jensen

AFNET terminates NOAH – AFNET 6 trial ahead of time

by

The NOAH – AFNET 6 trial which is conducted to evaluate the potential benefit of oral anticoagulation in patients with atrial high rate episodes (AHRE) is going to be terminated prematurely. The reason for early termination is an observed trend towards futility for efficacy combined with expected safety concerns. Following a recommendation of the study scientific committees, on 2 September 2022, AFNET decided to orderly terminate the NOAH – AFNET6 trial in the coming weeks. The study results will be available next year.

Better therapy for patients with heart failure and atrial fibrillation (CABA-HFPEF-DZHK27 trial)

by

The study “CABA-HFPEF-DZHK27” (CAtheter-Based Ablation of atrial fibrillation vs. conventional treatment in patients with Heart Failure with Preserved Ejection Fraction) is aiming for a better therapy for patients with heart failure and atrial fibrillation. Charité (Berlin, Germany) has the overall responsibility for the study. This trial is supported by German Centre for Cardiovascular Research (DZHK). Further information can be found in the press release (german only). 

Attaining sinus rhythm mediates improved outcomes with early rhythm control therapy of atrial fibrillation

by

A mediator analysis of the EAST – AFNET 4 trial dataset revealed the key factor for the effectiveness of early rhythm control (ERC) in patients with atrial fibrillation (AF): The presence of sinus rhythm at 12 months after randomization explains 81% of the outcome-reducing effect of ERC. Other factors, e. g. blood pressure or recurrent AF, only explain small portions of the effect. The results were presented by Professor Lars Eckardt, University Hospital Münster, Germany, at the annual congress of the European Society of Cardiology (ESC) in Barcelona, Spain, on 29.08.2022 [1], [2].

8th AFNET/EHRA Consensus Conference 2021 Paper published

by

Posts NEWS Mon, 08.08.2022 8th AFNET/EHRA Consensus Conference 2021 Paper published The 8th AFNET/EHRA Consensus Conference Paper 2021 “Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation” has been published: https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euac062/6650662  

Theme booklet of neurology

by

Posts NEWS Wen, 13.07.2022 Theme booklet of neurology The current issue of “theme booklet of neurology” reports on Atrial Fibrillation NETwork (AFNET), get your access here (german only).

EAST-AFNET 4 @ ESC 2022

by

Posts NEWS Thu, 07.07.2022 EAST-AFNET 4 @ ESC 2022 The newest subanalysis of the EAST-AFNET 4 study will be presented at this year’s ESC congress 2022 in Barcelona: Latest science in atrial fibrillationPredictors and mediators of improved outcomes on early rhythm control an analysis of the EAST AFNET – 4 data set.Monday, 29th of August … Read more

Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control

by

Posts NEWS Fri, 29.04.2022 Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control Press release Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control Early rhythm control therapy reduces cardiovascular complications compared to … Read more